Work

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-146570

Authors: Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Šimkovič, Iryna Kriachok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Min Hui Wang, Ting Yu, Paolo Ghia

Institutions: The Maria Sklodowska-Curie National Research Institute of Oncology, Medical University of Lublin, University Hospital Plzen, University Hospital Kralovske Vinohrady, Charles University, University Hospital Hradec Králové, National Cancer Institute, University of Debrecen, Hospital Universitario 12 De Octubre, University of New Brunswick, Saint John Regional Hospital, Barwon Health, Geelong Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, The Royal Wolverhampton NHS Trust, Nebraska Hematology-Oncology, Gachon University Gil Medical Center, Vita-Salute San Raffaele University

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3211568627

Cites:

Cited by: 21

Related to: 10